These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28787714)

  • 41. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
    Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
    Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials.
    Tian Hui Kwan A; Arfaie S; Therriault J; Rosa-Neto P; Gauthier S
    Dement Geriatr Cogn Disord; 2020; 49(4):334-348. PubMed ID: 33321511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy against amyloid pathology in Alzheimer's disease.
    Galimberti D; Ghezzi L; Scarpini E
    J Neurol Sci; 2013 Oct; 333(1-2):50-4. PubMed ID: 23299047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
    Petrushina I; Davtyan H; Hovakimyan A; Davtyan A; Passos GF; Cribbs DH; Ghochikyan A; Agadjanyan MG
    Mol Ther; 2017 Jan; 25(1):153-164. PubMed ID: 28129111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
    Solomon B
    Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
    Schenk DB; Seubert P; Grundman M; Black R
    Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy.
    Sengupta U; Nilson AN; Kayed R
    EBioMedicine; 2016 Apr; 6():42-49. PubMed ID: 27211547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy for Alzheimer's disease.
    Steinitz M
    Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Current trend of immunotherapy for Alzheimer's disease].
    Matsumoto SE; Tabira T
    Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy as treatment for Alzheimer's disease.
    Hawkes CA; McLaurin J
    Expert Rev Neurother; 2007 Nov; 7(11):1535-48. PubMed ID: 17997702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives].
    Karkos J
    Fortschr Neurol Psychiatr; 2004 Apr; 72(4):204-19. PubMed ID: 15095177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine.
    Yu YZ; Xu Q
    Hum Vaccin Immunother; 2016 Nov; 12(11):2801-2804. PubMed ID: 27379885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis.
    Foroutan N; Hopkins RB; Tarride JE; Florez ID; Levine M
    Clin Invest Med; 2019 Mar; 42(1):E53-E65. PubMed ID: 30904037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
    Boche D; Denham N; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural differences of amyloid-β fibrils revealed by antibodies from phage display.
    Droste P; Frenzel A; Steinwand M; Pelat T; Thullier P; Hust M; Lashuel H; Dübel S
    BMC Biotechnol; 2015 Jun; 15():57. PubMed ID: 26084577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I.
    Agadjanyan MG; Cribbs DH
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632
    [No Abstract]   [Full Text] [Related]  

  • 60. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.
    Lemere CA; Maier M; Jiang L; Peng Y; Seabrook TJ
    Rejuvenation Res; 2006; 9(1):77-84. PubMed ID: 16608400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.